person · Reporting owner

Angermayer Christian

Disclosed activity across 7 companies

Tapewire entity: 10108
SEC CIK: 0001845872

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Atai Beckley N.V.ATAI · Entity 72536	Director · 10% owner	September 30, 2025	October 02, 2025
Enhanced Group Inc.ENHA · Entity 6262	Director · 10% owner	September 17, 2026	September 22, 2026
Frontier Acquisition Corp.FRONU · Entity 115377	Director · Chief Executive Officer	March 10, 2021	March 16, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Atai Beckley N.V.

Report date September 30, 2025 · Filed October 02, 2025

Jointly reported with Apeiron Investment Group Ltd.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	IndirectBy Apeiron Investment Group Ltd.	53,412,414	Reported balance After 2025-09-30 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-09-30 · Conversion · Acquired 2,367,200 · Balance 53,412,414 F1: The conversion price for the Convertible Notes is EUR 17.00 per note.
Convertible NotesSEC Table II · derivative / convertible security · Expires 2025-09-30	IndirectBy Apeiron Investment Group Ltd.	0	Reported balance After 2025-09-30 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-09-30 · Conversion · Disposed 147,950 · Balance 0 F1: The conversion price for the Convertible Notes is EUR 17.00 per note. F2: The Convertible Notes were acquired in exchange for convertible notes issued by ATAI Life Sciences AG with substantially similar terms and economics.
Common SharesSEC Table I · non-derivative	IndirectBy Apeiron Presight Capital Fund II, L.P.	1,799,302	Reported balance Holding disclosure · report date 2025-09-30 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 1,799,302

Filing footnotes · ownership attribution and instrument terms

F1: The conversion price for the Convertible Notes is EUR 17.00 per note.

F2: The Convertible Notes were acquired in exchange for convertible notes issued by ATAI Life Sciences AG with substantially similar terms and economics.

Enhanced Group Inc.

Report date September 17, 2026 · Filed September 22, 2026

Jointly reported with Apeiron Investment Group Ltd., Enhanced Holdings LP

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	IndirectSee Footnote	43,343,818	Reported balance After 2026-09-17 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2026-09-17 · Purchase · Acquired 6,080,047 · Balance 43,343,818 F1: The securities reported herein are held of record by Apeiron Investment Group Ltd. ("Apeiron"), as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron, which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The securities reported herein are held of record by Apeiron Investment Group Ltd. ("Apeiron"), as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron, which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Frontier Acquisition Corp.

Report date March 10, 2021 · Filed March 16, 2021

This filing explicitly reported no securities owned.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Alto Neuroscience, Inc.

Report date February 06, 2024 · Filed March 06, 2024

Jointly reported with Apeiron Investment Group Ltd., Apeiron Presight Capital Fund II, L.P.

Section 16 reporting ended · disclosed 2024-03-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	251,881	Reported balance After 2024-02-06 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2024-02-06 · Conversion · Acquired 251,881 · Balance 251,881 F1: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F2: The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities.
Common StockSEC Table I · non-derivative	IndirectBy Apeiron Presight Capital Fund II, L.P.(	674,658	Reported balance After 2024-02-06 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2024-02-06 · Conversion · Acquired 674,658 · Balance 674,658 F1: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F3: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities.
Warrants to Purchase Series A Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2024-02-06 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-02-06 · Conversion · Disposed 444,561 · Balance 0 F4: In connection with the closing of the Issuer's initial public offering, the Warrants were exercised on a cashless basis into shares of Series A Preferred Stock, which were automatically converted into shares of Common Stock on a 2.2241 for 1 basis. F2: The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities.
Series A Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2024-02-06 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-02-06 · Conversion · Disposed 406,072 · Balance 0 F1: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F2: The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectBy Apeiron Presight Capital Fund II, L.P.	0	Reported balance After 2024-02-06 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-02-06 · Conversion · Disposed 1,063,918 · Balance 0 F1: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F3: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectBy Apeiron Presight Capital Fund II, L.P.	0	Reported balance After 2024-02-06 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-02-06 · Conversion · Disposed 416,665 · Balance 0 F5: In connection with the closing of the Issuer's initial public offering, each share of Series B Preferred automatically converted into common stock on a 2.1226069 for 1 basis. F1: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F3: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis.

F2: The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities.

F3: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities.

F4: In connection with the closing of the Issuer's initial public offering, the Warrants were exercised on a cashless basis into shares of Series A Preferred Stock, which were automatically converted into shares of Common Stock on a 2.2241 for 1 basis.

F5: In connection with the closing of the Issuer's initial public offering, each share of Series B Preferred automatically converted into common stock on a 2.1226069 for 1 basis.

AtaiBeckley Inc.

Report date September 11, 2026 · Filed September 11, 2026

Jointly reported with Apeiron Investment Group Ltd.

Section 16 reporting ended · disclosed 2026-09-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-09-11 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2026-09-11 · Disposition to issuer · Disposed 559,232 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. F2: At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, converted into the right to receive (i) $6.75 per share in cash, without interest, plus (ii) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding.
Common StockSEC Table I · non-derivative	IndirectBy ApeironInvestmentGroup Ltd.	Reported balance After 2026-09-11 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2026-09-11 · Disposition to issuer · Disposed 53,398,214 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. F2: At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, converted into the right to receive (i) $6.75 per share in cash, without interest, plus (ii) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding. F3: The Reporting Person's prior Form 4 inadvertently reported an incorrect beneficial ownership total, which has been corrected in this Form 4.
Common StockSEC Table I · non-derivative	IndirectBy ApeironPresightCapital FundII, L.P.	Reported balance After 2026-09-11 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2026-09-11 · Disposition to issuer · Disposed 1,799,302 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. F2: At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, converted into the right to receive (i) $6.75 per share in cash, without interest, plus (ii) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.68 · Expires 2030-08-20	Direct	Reported balance After 2026-09-11 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-09-11 · Disposition to issuer · Disposed 624,000 · Balance 0 F4: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.84 · Expires 2032-05-25	Direct	Reported balance After 2026-09-11 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-09-11 · Disposition to issuer · Disposed 64,000 · Balance 0 F4: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.88 · Expires 2033-05-23	Direct	Reported balance After 2026-09-11 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-09-11 · Disposition to issuer · Disposed 17,930 · Balance 0 F4: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.64 · Expires 2034-01-05	Direct	Reported balance After 2026-09-11 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-09-11 · Disposition to issuer · Disposed 1,247,932 · Balance 0 F4: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.49 · Expires 2035-06-02	Direct	Reported balance After 2026-09-11 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-09-11 · Disposition to issuer · Disposed 131,698 · Balance 0 F4: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.25 · Expires 2035-06-26	Direct	Reported balance After 2026-09-11 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-09-11 · Disposition to issuer · Disposed 103,000 · Balance 0 F4: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.50 · Expires 2036-06-04	Direct	Reported balance After 2026-09-11 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2026-09-11 · Disposition to issuer · Disposed 121,968 · Balance 0 F4: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent.

F2: At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, converted into the right to receive (i) $6.75 per share in cash, without interest, plus (ii) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding.

F3: The Reporting Person's prior Form 4 inadvertently reported an incorrect beneficial ownership total, which has been corrected in this Form 4.

F4: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

BIONOMICS LTD/ADR

Report date July 01, 2024 · Filed October 07, 2024

Jointly reported with Apeiron Investment Group Ltd., Apeiron Presight Capital Fund II, L.P.

Section 16 reporting ended · disclosed 2024-10-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	IndirectBy Apeiron Presight Capital Fund II, L.P.	125,996,580	Reported balance After 2024-10-02 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2024-10-02 · Sale · Disposed 90,806 · Balance 125,996,580 F1: Includes Ordinary Shares represented by American Depositary Shares. F2: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities.
Ordinary SharesSEC Table I · non-derivative	IndirectBy Apeiron Presight Capital Fund II, L.P.	93,469,320	Reported balance After 2024-10-03 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2024-10-03 · Sale · Disposed 180,707 · Balance 93,469,320 F1: Includes Ordinary Shares represented by American Depositary Shares. F2: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities.
Ordinary SharesSEC Table I · non-derivative	IndirectBy Apeiron Presight Capital Fund II, L.P.	93,369,060	Reported balance After 2024-10-04 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2024-10-04 · Sale · Disposed 557 · Balance 93,369,060 F1: Includes Ordinary Shares represented by American Depositary Shares. F2: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities.
Ordinary SharesSEC Table I · non-derivative	IndirectBy Apeiron Investment Group Ltd.	183,121,441	Reported balance Holding disclosure · report date 2024-07-01 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 183,121,441 F1: Includes Ordinary Shares represented by American Depositary Shares. F3: The reportable securities are held by Apeiron. Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities.

Filing footnotes · ownership attribution and instrument terms

F1: Includes Ordinary Shares represented by American Depositary Shares.

F2: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities.

F3: The reportable securities are held by Apeiron. Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities.

Faeth Therapeutics, Inc.

Report date June 01, 2023 · Filed June 02, 2023

Jointly reported with Apeiron Investment Group Ltd., Presight Sensei Co-Invest Fund, L.P., Presight Co-Invest Management, L.L.C.

Section 16 reporting ended · disclosed 2023-06-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Apeiron Investment Group Ltd.	0	Reported balance After 2023-06-01 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2023-06-01 · Sale · Disposed 2,485,923 · Balance 0 F1: This Form 4 is filed jointly by Apeiron Investment Group Ltd. ("Apeiron"), Christian Angermayer, Presight Sensei Co-Invest Fund, L.P. ("Presight Co-Invest") and Presight Sensei Co-Invest Management, L.L.C. ("Presight Co-Invest Management", and collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that previously beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. F2: Securities owned directly by Apeiron. Mr. Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities owned directly by Apeiron.
Common StockSEC Table I · non-derivative	IndirectBy Presight Sensei Co-Invest Fund, L.P.	0	Reported balance After 2023-06-01 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2023-06-01 · Sale · Disposed 955,738 · Balance 0 F1: This Form 4 is filed jointly by Apeiron Investment Group Ltd. ("Apeiron"), Christian Angermayer, Presight Sensei Co-Invest Fund, L.P. ("Presight Co-Invest") and Presight Sensei Co-Invest Management, L.L.C. ("Presight Co-Invest Management", and collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that previously beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. F3: Securities owned directly by Presight Co-Invest. As the general partner of Presight Co-Invest, Presight Co-Invest Management may be deemed to beneficially own the securities owned directly by Presight Co-Invest. As the sole member of Presight Co-Invest Management, Apeiron may be deemed to beneficially own the securities owned directly by Presight Co-Invest. Mr. Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities owned directly by Presight Co-Invest.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 is filed jointly by Apeiron Investment Group Ltd. ("Apeiron"), Christian Angermayer, Presight Sensei Co-Invest Fund, L.P. ("Presight Co-Invest") and Presight Sensei Co-Invest Management, L.L.C. ("Presight Co-Invest Management", and collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that previously beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2: Securities owned directly by Apeiron. Mr. Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities owned directly by Apeiron.

F3: Securities owned directly by Presight Co-Invest. As the general partner of Presight Co-Invest, Presight Co-Invest Management may be deemed to beneficially own the securities owned directly by Presight Co-Invest. As the sole member of Presight Co-Invest Management, Apeiron may be deemed to beneficially own the securities owned directly by Presight Co-Invest. Mr. Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities owned directly by Presight Co-Invest.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 06, 2024 Filed Mar 6, 2024 14:15 UTC	Alto Neuroscience, Inc. ANRO · Entity 4755	ConversionSeries B Preferred Stock · Derivative	416,665	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-026885 · ownership.xml · derivative · entry 6 Apeiron Investment Group Ltd. · CIK 0001845711 · See Remarks Apeiron Presight Capital Fund II, L.P. · CIK 0001840676 · See Remarks Angermayer Christian · CIK 0001845872 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Apeiron Presight Capital Fund II, L.P. Disclosed balance after: 0 Underlying: Common Stock · 196,299 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: In connection with the closing of the Issuer's initial public offering, each share of Series B Preferred automatically converted into common stock on a 2.1226069 for 1 basis. F1 · price: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F5 · derivative.exercise_date: In connection with the closing of the Issuer's initial public offering, each share of Series B Preferred automatically converted into common stock on a 2.1226069 for 1 basis. F5 · derivative.expiration_date: In connection with the closing of the Issuer's initial public offering, each share of Series B Preferred automatically converted into common stock on a 2.1226069 for 1 basis. F3 · ownership.nature: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities. Read SEC document
February 06, 2024 Filed Mar 6, 2024 14:15 UTC	Alto Neuroscience, Inc. ANRO · Entity 4755	ConversionSeries A Preferred Stock · Derivative	1,063,918	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-026885 · ownership.xml · derivative · entry 5 Apeiron Investment Group Ltd. · CIK 0001845711 · See Remarks Apeiron Presight Capital Fund II, L.P. · CIK 0001840676 · See Remarks Angermayer Christian · CIK 0001845872 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Apeiron Presight Capital Fund II, L.P. Disclosed balance after: 0 Underlying: Common Stock · 478,359 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F1 · price: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F1 · derivative.exercise_date: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F1 · derivative.expiration_date: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F3 · ownership.nature: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities. Read SEC document
February 06, 2024 Filed Mar 6, 2024 14:15 UTC	Alto Neuroscience, Inc. ANRO · Entity 4755	ConversionSeries A Preferred Stock · Derivative	406,072	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-026885 · ownership.xml · derivative · entry 4 Apeiron Investment Group Ltd. · CIK 0001845711 · See Remarks Apeiron Presight Capital Fund II, L.P. · CIK 0001840676 · See Remarks Angermayer Christian · CIK 0001845872 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 182,577 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F1 · price: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F1 · derivative.exercise_date: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F1 · derivative.expiration_date: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F2 · ownership.direct: The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities. Read SEC document
February 06, 2024 Filed Mar 6, 2024 14:15 UTC	Alto Neuroscience, Inc. ANRO · Entity 4755	ConversionWarrants to Purchase Series A Preferred Stock · Derivative	444,561	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-026885 · ownership.xml · derivative · entry 3 Apeiron Investment Group Ltd. · CIK 0001845711 · See Remarks Apeiron Presight Capital Fund II, L.P. · CIK 0001840676 · See Remarks Angermayer Christian · CIK 0001845872 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 69,304 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: In connection with the closing of the Issuer's initial public offering, the Warrants were exercised on a cashless basis into shares of Series A Preferred Stock, which were automatically converted into shares of Common Stock on a 2.2241 for 1 basis. F4 · price: In connection with the closing of the Issuer's initial public offering, the Warrants were exercised on a cashless basis into shares of Series A Preferred Stock, which were automatically converted into shares of Common Stock on a 2.2241 for 1 basis. F4 · derivative.exercise_date: In connection with the closing of the Issuer's initial public offering, the Warrants were exercised on a cashless basis into shares of Series A Preferred Stock, which were automatically converted into shares of Common Stock on a 2.2241 for 1 basis. F4 · derivative.expiration_date: In connection with the closing of the Issuer's initial public offering, the Warrants were exercised on a cashless basis into shares of Series A Preferred Stock, which were automatically converted into shares of Common Stock on a 2.2241 for 1 basis. F2 · ownership.direct: The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities. Read SEC document
February 06, 2024 Filed Mar 6, 2024 14:15 UTC	Alto Neuroscience, Inc. ANRO · Entity 4755	ConversionCommon Stock	674,658	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-026885 · ownership.xml · nonDerivative · entry 2 Apeiron Investment Group Ltd. · CIK 0001845711 · See Remarks Apeiron Presight Capital Fund II, L.P. · CIK 0001840676 · See Remarks Angermayer Christian · CIK 0001845872 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Apeiron Presight Capital Fund II, L.P.( Disclosed balance after: 674,658 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F3 · ownership.nature: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities. Read SEC document
February 06, 2024 Filed Mar 6, 2024 14:15 UTC	Alto Neuroscience, Inc. ANRO · Entity 4755	ConversionCommon Stock	251,881	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-026885 · ownership.xml · nonDerivative · entry 1 Apeiron Investment Group Ltd. · CIK 0001845711 · See Remarks Apeiron Presight Capital Fund II, L.P. · CIK 0001840676 · See Remarks Angermayer Christian · CIK 0001845872 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 251,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F2 · ownership.direct: The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities. Read SEC document
January 05, 2024 Filed Jan 9, 2024 17:00 UTC	Atai Beckley N.V. ATAI · Entity 72536	GrantStock Option · Derivative	642,000	$0.00 Strike: $1.64	$0.00	Disclosure SEC source: 0000950170-24-003398 · ownership.xml · derivative · entry 1 Angermayer Christian · CIK 0001845872 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 642,000 Underlying: Common Shares · 642,000 shares Expires 2034-01-05 F1 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares on January 5, 2025, and will vest with respect to the remaining shares in 36 monthly installments thereafter. Read SEC document
June 01, 2023 Filed Jun 2, 2023 21:03 UTC	Faeth Therapeutics, Inc. SNSE · Entity 5029	SaleCommon Stock	955,738	$1.58	$1,510,066.04	Disclosure SEC source: 0000921895-23-001420 · form413506002_06022023.xml · nonDerivative · entry 2 Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Angermayer Christian · CIK 0001845872 · 10% owner Presight Sensei Co-Invest Fund, L.P. · CIK 0001828422 · See Explanation of Responses Presight Co-Invest Management, L.L.C. · CIK 0001846009 · See Explanation of Responses Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Presight Sensei Co-Invest Fund, L.P. Disclosed balance after: 0 F1 · security: This Form 4 is filed jointly by Apeiron Investment Group Ltd. ("Apeiron"), Christian Angermayer, Presight Sensei Co-Invest Fund, L.P. ("Presight Co-Invest") and Presight Sensei Co-Invest Management, L.L.C. ("Presight Co-Invest Management", and collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that previously beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. F3 · ownership.nature: Securities owned directly by Presight Co-Invest. As the general partner of Presight Co-Invest, Presight Co-Invest Management may be deemed to beneficially own the securities owned directly by Presight Co-Invest. As the sole member of Presight Co-Invest Management, Apeiron may be deemed to beneficially own the securities owned directly by Presight Co-Invest. Mr. Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities owned directly by Presight Co-Invest. Read SEC document
June 01, 2023 Filed Jun 2, 2023 21:03 UTC	Faeth Therapeutics, Inc. SNSE · Entity 5029	SaleCommon Stock	2,485,923	$1.58	$3,927,758.34	Disclosure SEC source: 0000921895-23-001420 · form413506002_06022023.xml · nonDerivative · entry 1 Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Angermayer Christian · CIK 0001845872 · 10% owner Presight Sensei Co-Invest Fund, L.P. · CIK 0001828422 · See Explanation of Responses Presight Co-Invest Management, L.L.C. · CIK 0001846009 · See Explanation of Responses Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Apeiron Investment Group Ltd. Disclosed balance after: 0 F1 · security: This Form 4 is filed jointly by Apeiron Investment Group Ltd. ("Apeiron"), Christian Angermayer, Presight Sensei Co-Invest Fund, L.P. ("Presight Co-Invest") and Presight Sensei Co-Invest Management, L.L.C. ("Presight Co-Invest Management", and collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that previously beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. F2 · ownership.nature: Securities owned directly by Apeiron. Mr. Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities owned directly by Apeiron. Read SEC document
May 23, 2023 Filed May 25, 2023 16:16 UTC	Atai Beckley N.V. ATAI · Entity 72536	GrantStock Option · Derivative	64,000	$0.00 Strike: $1.88	$0.00	Disclosure SEC source: 0000950170-23-024239 · ownership.xml · derivative · entry 1 Angermayer Christian · CIK 0001845872 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,000 Underlying: Common Shares · 64,000 shares Expires 2033-05-23 F1 · derivative.exercise_date: The stock option shall vest on the earlier of the day before the ATAI Life Sciences N.V's next annual meeting or May 16, 2024 Read SEC document
March 29, 2023 Filed Mar 29, 2023 16:05 UTC	Atai Beckley N.V. ATAI · Entity 72536	PurchaseCommon Shares	1,214,297	$1.32	$1,600,443.45	Disclosure SEC source: 0000899243-23-009973 · doc4.xml · nonDerivative · entry 1 Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Angermayer Christian · CIK 0001845872 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Apeiron Investment Group Ltd. Disclosed balance after: 32,086,697 Read SEC document
February 23, 2023 Filed Feb 28, 2023 01:10 UTC	Faeth Therapeutics, Inc. SNSE · Entity 5029	PurchaseCommon Stock	1,100	$1.60	$1,762.53	Disclosure SEC source: 0000921895-23-000615 · form413506002_02272023.xml · nonDerivative · entry 2 Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Angermayer Christian · CIK 0001845872 · 10% owner Presight Sensei Co-Invest Fund, L.P. · CIK 0001828422 · See Explanation of Responses Presight Co-Invest Management, L.L.C. · CIK 0001846009 · See Explanation of Responses Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Apeiron Investment Group Ltd. Disclosed balance after: 2,485,923 F1 · security: This Form 4 is filed jointly by Apeiron Investment Group Ltd. ("Apeiron"), Christian Angermayer, Presight Sensei Co-Invest Fund, L.P. ("Presight Co-Invest") and Presight Sensei Co-Invest Management, L.L.C. ("Presight Co-Invest Management", and collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that beneficially owns over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. F2 · ownership.nature: Securities owned directly by Apeiron. Mr. Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities owned directly by Apeiron. Read SEC document
February 23, 2023 Filed Feb 28, 2023 01:10 UTC	Faeth Therapeutics, Inc. SNSE · Entity 5029	PurchaseCommon Stock	1,100	$1.62	$1,776.50	Disclosure SEC source: 0000921895-23-000615 · form413506002_02272023.xml · nonDerivative · entry 1 Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Angermayer Christian · CIK 0001845872 · 10% owner Presight Sensei Co-Invest Fund, L.P. · CIK 0001828422 · See Explanation of Responses Presight Co-Invest Management, L.L.C. · CIK 0001846009 · See Explanation of Responses Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Apeiron Investment Group Ltd. Disclosed balance after: 2,484,823 F1 · security: This Form 4 is filed jointly by Apeiron Investment Group Ltd. ("Apeiron"), Christian Angermayer, Presight Sensei Co-Invest Fund, L.P. ("Presight Co-Invest") and Presight Sensei Co-Invest Management, L.L.C. ("Presight Co-Invest Management", and collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that beneficially owns over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. F2 · ownership.nature: Securities owned directly by Apeiron. Mr. Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities owned directly by Apeiron. Read SEC document
May 25, 2022 Filed May 27, 2022 17:49 UTC	Atai Beckley N.V. ATAI · Entity 72536	GrantStock Option · Derivative	64,000	$0.00 Strike: $3.84	$0.00	Disclosure SEC source: 0000899243-22-019968 · doc4.xml · derivative · entry 1 Angermayer Christian · CIK 0001845872 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,000 Underlying: Common Shares · 64,000 shares Expires 2032-05-25 F1 · derivative.exercise_date: The stock option shall vest on the earlier of the day before ATAI Life Sciences N.V.'s next annual meeting or May 25, 2023. Read SEC document
April 29, 2022 Filed May 2, 2022 16:15 UTC	Atai Beckley N.V. ATAI · Entity 72536	PurchaseCommon Shares	21,900	$4.47	$97,801.02	Disclosure SEC source: 0000899243-22-016117 · doc4.xml · nonDerivative · entry 2 Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Angermayer Christian · CIK 0001845872 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Apeiron Presight Capital Fund II, L.P. Disclosed balance after: 1,799,302 F2 · price: The price reported in Column 4 is a weighted average price. The common shares were purchased in multiple transactions at prices ranging from $4.28 to $4.66 per share. The reporting persons undertake to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
April 28, 2022 Filed May 2, 2022 16:15 UTC	Atai Beckley N.V. ATAI · Entity 72536	PurchaseCommon Shares	34,700	$4.46	$154,689.13	Disclosure SEC source: 0000899243-22-016117 · doc4.xml · nonDerivative · entry 1 Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Angermayer Christian · CIK 0001845872 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Apeiron Presight Capital Fund II, L.P. Disclosed balance after: 1,777,402 F1 · price: The price reported in Column 4 is a weighted average price. The common shares were purchased in multiple transactions at prices ranging from $4.22 to $4.64 per share. The reporting persons undertake to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
April 27, 2022 Filed Apr 28, 2022 16:26 UTC	Atai Beckley N.V. ATAI · Entity 72536	PurchaseCommon Shares	19,803	$4.64	$91,939.39	Disclosure SEC source: 0000899243-22-015852 · doc4.xml · nonDerivative · entry 2 Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Angermayer Christian · CIK 0001845872 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Apeiron Presight Capital Fund II, L.P. Disclosed balance after: 1,742,702 F2 · price: The price reported in Column 4 is a weighted average price. The common shares were purchased in multiple transactions at prices ranging from $4.54 to $4.77 per share. The reporting persons undertake to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
April 26, 2022 Filed Apr 28, 2022 16:26 UTC	Atai Beckley N.V. ATAI · Entity 72536	PurchaseCommon Shares	46,207	$4.69	$216,627.66	Disclosure SEC source: 0000899243-22-015852 · doc4.xml · nonDerivative · entry 1 Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Angermayer Christian · CIK 0001845872 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Apeiron Presight Capital Fund II, L.P. Disclosed balance after: 1,722,899 F1 · price: The price reported in Column 4 is a weighted average price. The common shares were purchased in multiple transactions at prices ranging from $4.58 to $4.80 per share. The reporting persons undertake to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
April 25, 2022 Filed Apr 26, 2022 16:15 UTC	Atai Beckley N.V. ATAI · Entity 72536	PurchaseCommon Shares	8,961	$4.78	$42,842.54	Disclosure SEC source: 0000899243-22-015653 · doc4.xml · nonDerivative · entry 2 Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Angermayer Christian · CIK 0001845872 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Apeiron Presight Capital Fund II, L.P. Disclosed balance after: 1,676,692 F2 · price: The price reported in Column 4 is a weighted average price. The common shares were purchased in multiple transactions at prices ranging from $4.72 to $4.80 per share. The reporting persons undertake to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
April 22, 2022 Filed Apr 26, 2022 16:15 UTC	Atai Beckley N.V. ATAI · Entity 72536	PurchaseCommon Shares	52,820	$4.83	$254,962.14	Disclosure SEC source: 0000899243-22-015653 · doc4.xml · nonDerivative · entry 1 Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Angermayer Christian · CIK 0001845872 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Apeiron Presight Capital Fund II, L.P. Disclosed balance after: 1,667,731 F1 · price: The price reported in Column 4 is a weighted average price. The common shares were purchased in multiple transactions at prices ranging from $4.77 to $4.90 per share. The reporting persons undertake to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
April 21, 2022 Filed May 3, 2022 16:16 UTC	Atai Beckley N.V. ATAI · Entity 72536	PurchaseCommon Shares	68,688	$4.95	$340,039.94	Disclosure SEC source: 0000899243-22-016301 · doc4.xml · nonDerivative · entry 2 Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Angermayer Christian · CIK 0001845872 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Apeiron Presight Capital Fund II, L.P. Disclosed balance after: 1,614,911 F2 · price: The price reported in Column 4 is a weighted average price. The common shares were purchased in multiple transactions at prices ranging from $4.87 to $5.10 per share. The reporting persons undertake to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
April 20, 2022 Filed May 3, 2022 16:16 UTC	Atai Beckley N.V. ATAI · Entity 72536	PurchaseCommon Shares	67,703	$5.09	$344,513.49	Disclosure SEC source: 0000899243-22-016301 · doc4.xml · nonDerivative · entry 1 Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Angermayer Christian · CIK 0001845872 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Apeiron Presight Capital Fund II, L.P. Disclosed balance after: 1,546,223 F1 · price: The price reported in Column 4 is a weighted average price. The common shares were purchased in multiple transactions at prices ranging from $5.02 to $5.20 per share. The reporting persons undertake to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
April 19, 2022 Filed Apr 20, 2022 16:30 UTC	Atai Beckley N.V. ATAI · Entity 72536	PurchaseCommon Shares	65,315	$5.13	$334,739.38	Disclosure SEC source: 0000899243-22-015168 · doc4.xml · nonDerivative · entry 2 Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Angermayer Christian · CIK 0001845872 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Apeiron Presight Capital Fund II, L.P. Disclosed balance after: 1,478,520 F2 · price: The price reported in Column 4 is a weighted average price. The common shares were purchased in multiple transactions at prices ranging from $5.00 to $5.20 per share. The reporting persons undertake to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
April 18, 2022 Filed Apr 20, 2022 16:30 UTC	Atai Beckley N.V. ATAI · Entity 72536	PurchaseCommon Shares	54,322	$5.11	$277,656.04	Disclosure SEC source: 0000899243-22-015168 · doc4.xml · nonDerivative · entry 1 Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Angermayer Christian · CIK 0001845872 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Apeiron Presight Capital Fund II, L.P. Disclosed balance after: 1,413,205 F1 · price: The price reported in Column 4 is a weighted average price. The common shares were purchased in multiple transactions at prices ranging from $5.06 to $5.20 per share. The reporting persons undertake to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
April 14, 2022 Filed Apr 18, 2022 16:15 UTC	Atai Beckley N.V. ATAI · Entity 72536	PurchaseCommon Shares	4,967	$5.19	$25,778.73	Disclosure SEC source: 0000899243-22-014963 · doc4.xml · nonDerivative · entry 1 Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Angermayer Christian · CIK 0001845872 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Apeiron Presight Capital Fund II, L.P. Disclosed balance after: 1,358,883 F1 · price: The price reported in Column 4 is a weighted average price. The common shares were purchased in multiple transactions at prices ranging from $5.13 to $5.20 per share. The reporting persons undertake to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
April 12, 2022 Filed Apr 14, 2022 16:15 UTC	Atai Beckley N.V. ATAI · Entity 72536	PurchaseCommon Shares	55,197	$4.88	$269,560.07	Disclosure SEC source: 0000899243-22-014797 · doc4.xml · nonDerivative · entry 1 Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Angermayer Christian · CIK 0001845872 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Apeiron Presight Capital Fund II, L.P. Disclosed balance after: 1,353,916 F1 · price: The price reported in Column 4 is a weighted average price. The common shares were purchased in multiple transactions at prices ranging from $4.84 to $4.90 per share. The reporting persons undertake to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
April 11, 2022 Filed Apr 12, 2022 16:30 UTC	Atai Beckley N.V. ATAI · Entity 72536	PurchaseCommon Shares	53,926	$4.83	$260,554.25	Disclosure SEC source: 0000899243-22-014575 · doc4.xml · nonDerivative · entry 2 Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Angermayer Christian · CIK 0001845872 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Apeiron Presight Capital Fund II, L.P. Disclosed balance after: 1,298,719 F2 · price: The price reported in Column 4 is a weighted average price. The common shares were purchased in multiple transactions at prices ranging from $4.78 to $4.90 per share. The reporting persons undertake to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
April 08, 2022 Filed Apr 12, 2022 16:30 UTC	Atai Beckley N.V. ATAI · Entity 72536	PurchaseCommon Shares	57,689	$4.81	$277,639.85	Disclosure SEC source: 0000899243-22-014575 · doc4.xml · nonDerivative · entry 1 Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Angermayer Christian · CIK 0001845872 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Apeiron Presight Capital Fund II, L.P. Disclosed balance after: 1,244,793 F1 · price: The price reported in Column 4 is a weighted average price. The common shares were purchased in multiple transactions at prices ranging from $4.70 to $4.90 per share. The reporting persons undertake to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
April 06, 2022 Filed Apr 7, 2022 16:15 UTC	Atai Beckley N.V. ATAI · Entity 72536	PurchaseCall Option (right to purchase) · Derivative	1,000,000	$0.96 Strike: $10.10	$959,800.00	Disclosure SEC source: 0000899243-22-014260 · doc4.xml · derivative · entry 1 Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Angermayer Christian · CIK 0001845872 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Apeiron Investment Group Ltd. Disclosed balance after: 1,000,000 Underlying: Common Shares · 1,000,000 shares Expires 2025-03-31 F1 · derivative.underlying_shares: On April 6, 2022, Apeiron Investment Group Ltd. ("Apeiron") finalized a capped call option transaction pursuant to which it shall have the right to purchase 1,000,000 Common Shares on March 31, 2025 at a price per share of $10.1030. In the event the trading price of the Common Shares exceeds $17.1751 on March 31, 2025, however, the number of shares that Apeiron shall be entitled to purchase pursuant to the option transaction shall be reduced proportionately to the amount by which such trading price exceeds $17.1751. Apeiron may also elect to settle the option transaction in cash in certain circumstances. Read SEC document
September 10, 2021 Filed Sep 13, 2021 16:30 UTC	Atai Beckley N.V. ATAI · Entity 72536	GrantStock Option · Derivative	128,000	$0.00 Strike: $16.46	$0.00	Disclosure SEC source: 0000899243-21-035676 · doc4.xml · derivative · entry 1 Angermayer Christian · CIK 0001845872 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,000 Underlying: Common Shares · 128,000 shares Expires 2031-09-10 F1 · derivative.exercise_date: The stock option shall vest with respect to a third of the underlying common shares on June 17, 2022 and in 24 substantially equal monthly installments thereafter until June 17, 2024. Read SEC document
June 22, 2021 Filed Jun 24, 2021 16:15 UTC	Atai Beckley N.V. ATAI · Entity 72536	PurchaseCommon Shares	700,000	$15.00	$10,500,000.00	Disclosure SEC source: 0000899243-21-025736 · doc4.xml · nonDerivative · entry 1 Angermayer Christian · CIK 0001845872 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Apeiron Investment Group Ltd. Disclosed balance after: 20,185,200 F1 · ownership.nature: Apeiron Investment Group Ltd. is the co-managing member of Presight Capital Management I, LLC, which is the general partner of Presight II, L.P. Therefore, Apeiron Investment Group Ltd. may be deemed to share beneficial ownership of the Common Shares held by Presight II, L.P. Apeiron Investment Group Ltd. is owned and controlled by Christian Angermayer. Mr. Angermayer may be deemed to have beneficial ownership over the shares held by Apeiron Investment Group Ltd. and Presight II, L.P. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.